Ask Warren

Pharos iBio

388870 · KOSDAQ · ₩388870 · 파로스아이바이오

₩5,580▼ ₩200 (3.46%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue—————₩0——
Cost of sales—————₩0——
Gross profit—————₩0——
Operating income−₩2.3B−₩2.4B−₩2.9B−₩3B−₩2.4B−₩3.1B−₩2.9B−₩3B
Net income−₩2.3B−₩2.2B−₩3.1B−₩1.8B−₩2.8B−₩3B−₩2.2B−₩2.5B
Net income to shareholders−₩2.3B−₩2.2B−₩3B−₩1.7B−₩2.9B−₩3B−₩2B−₩2.6B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩26B₩28B₩30B₩12B₩14B₩17B₩20B₩21B
Current assets₩23B₩24B₩26B₩9.3B₩10B₩14B₩16B₩18B
Cash and equivalents₩5.4B₩7.3B₩26B₩5.4B₩5B₩4.5B₩6.4B₩4.6B
Total liabilities₩17B₩16B₩16B₩985M₩815M₩1.2B₩1B₩656M
Current liabilities₩817M₩1B₩1.4B₩819M₩612M₩1.2B₩973M₩607M
Borrowings₩8.6B₩8.1B₩7.7B₩250M₩286M₩85M₩124M₩163M
Total equity₩9.7B₩12B₩14B₩11B₩13B₩16B₩19B₩20B
Shareholders' equity₩9.7B₩12B₩14B₩11B₩13B₩16B₩19B₩20B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩1.3B−₩2.4B−₩1.6B−₩1.3B−₩2.7B−₩2.8B−₩1.6B−₩1.8B
Capital spending₩380M₩19M₩0₩6.6M₩1.3M₩7.4M₩321M−₩42M
Free cash flow−₩1.7B−₩2.4B−₩1.6B−₩1.3B−₩2.7B−₩2.8B−₩1.9B−₩1.8B

Consolidated where available. Amounts in won.

Also known as: Pharos iBio / 파로스아이바이오 / 388870 / KRX:388870

Source: KRX statistical information